RxDoctor Payments Data

Emily Wallace

Family · Austin, TXNPI 1902457120

Payments from drug & device makers

$365in general payments, 2019–2025

Across 9 payments — averaging $40.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CMP Pharma, Inc.$84
  • Xeris Pharmaceuticals, Inc.$70
  • Sumitomo Pharma America, Inc.$65
  • Otsuka America Pharmaceutical, Inc.$50
  • Acadia Pharmaceuticals Inc$42
  • SK Life Science, Inc.$35
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$365 in reported general payments places this provider in the 45th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$132,312
Medicare patients
159
Services billed
1,363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate23$56,705
EliquisApixaban190$53,933
TrulicityDulaglutide33$31,769
MyrbetriqMirabegron47$10,911
Incruse ElliptaUmeclidinium Bromide23$8,267
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,398
XareltoRivaroxaban24$6,505
TradjentaLinagliptin23$6,073
JardianceEmpagliflozin19$5,676
Breo ElliptaFluticasone/Vilanterol12$5,211
Gabapentin232$4,958
GemtesaVibegron19$4,651
Ursodiol12$4,014
Mirtazapine130$3,609
Divalproex Sodium36$3,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$42$56,70523 claims
Sumitomo Pharma America, Inc.Gemtesa$65$4,65119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 15,456 family providers in Texas.

Other family in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →